Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EORTC CLTF 2021 | Mechanism of CXCR4 inhibition

Lilach Moyal • 15 Oct 2021
EORTC CLTF 2021
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases

Lilach Moyal, PhD, Tel Aviv University, Tel Aviv, Israel, explains how inhibition of the CXCR4/CXCL12 axis leads to tumor cell death. CXCR4 antagonists bind to the CXCR4 receptor and prevent CXCL12 from inducing signaling cascades resulting in chemotaxis and survival of malignant cells, which eventually results in their apoptosis. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

More from Lilach Moyal

1:08
The CXCR4/CXCL12 axis as a potential therapeutic target in mycosis fungoides
Lilach Moyal • 15 Oct 2021
0:57
The effect of CXCR4 inhibition on malignant cells
Lilach Moyal • 15 Oct 2021
1:43
Potential clinical applications of CXCR4 antagonists in cancer
Lilach Moyal • 15 Oct 2021
0:58
Next steps in the development of CXCR4 inhibitors for mycosis fungoides
Lilach Moyal • 15 Oct 2021

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals